Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol: Off J Am Soc Clin Oncol. 2017;35:893–911.
Asselin BL, Devidas M, Chen L, et al. Cardioprotection and Safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404. J Clin Oncol: Off J Am Soc Clin Oncol. 2016;34:854–62.
Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–8.
Article CAS PubMed Google Scholar
Catanzaro MP, Weiner A, Kaminaris A, et al. Doxorubicin-induced cardiomyocyte death is mediated by unchecked mitochondrial fission and mitophagy. FASEB J: Off Publ Fed Am Soc Exp Biol. 2019;33:11096–108.
Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol. 2017;70:2552–65.
Article PubMed PubMed Central Google Scholar
Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 2010;6:322–9.
Article CAS PubMed Google Scholar
Davis JL. A practical system for narcotic control within the OR/PACU. J Post Anesth Nurs. 1989;4:32–5.
Gu J, Song ZP, Gui DM, Hu W, Chen YG, Zhang DD. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in lymphoma nude mice by heme oxygenase-1 induction. Cardiovasc Toxicol. 2012;12:341–9.
Article CAS PubMed Google Scholar
Gu J, Hu W, Song ZP, Chen YG, Zhang DD, Wang CQ. Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity. Int Immunopharmacol. 2016;32:1–7.
Gu J, Fan YQ, Zhang HL, et al. Resveratrol suppresses doxorubicin-induced cardiotoxicity by disrupting E2F1 mediated autophagy inhibition and apoptosis promotion. Biochem Pharmacol. 2018;150:202–13.
Article CAS PubMed Google Scholar
Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17:528–42.
Article CAS PubMed Google Scholar
Li DL, Wang ZV, Ding G, et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation. 2016;133:1668–87.
Article CAS PubMed PubMed Central Google Scholar
Li M, Sala V, De Santis MC, et al. Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation. 2018;138:696–711.
Article CAS PubMed Google Scholar
Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11:950–61.
Article CAS PubMed PubMed Central Google Scholar
Mariño G, Pietrocola F, Kong Y, et al. Dimethyl α-ketoglutarate inhibits maladaptive autophagy in pressure overload-induced cardiomyopathy. Autophagy. 2014;10:930–2.
Article PubMed PubMed Central Google Scholar
Nakai A, Yamaguchi O, Takeda T, et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med. 2007;13:619–24.
Article CAS PubMed Google Scholar
Pasquier B. SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with MTOR inhibition in tumor cells. Autophagy. 2015;11:725–6.
Article CAS PubMed PubMed Central Google Scholar
Ronan B, Flamand O, Vescovi L, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol. 2014;10:1013–9.
Article CAS PubMed Google Scholar
Shirakabe A, Zhai P, Ikeda Y, et al. Drp1-dependent mitochondrial autophagy plays a protective role against pressure overload-induced mitochondrial dysfunction and heart failure. Circulation. 2016;133:1249–63.
Article CAS PubMed PubMed Central Google Scholar
Song E, Da Eira D, Jani S, et al. Cardiac autophagy deficiency attenuates ANP production and disrupts myocardial-adipose cross talk, leading to increased fat accumulation and metabolic dysfunction. Diabetes. 2021;70:51–61.
Article CAS PubMed Google Scholar
Sun X, Meng H, Xiao J, Liu F, Du J, Zeng H. Pretreatment of 3-MA prevents doxorubicin-induced cardiotoxicity through inhibition of autophagy initiation. Toxicology. 2023;490:153512.
Article CAS PubMed Google Scholar
Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol: Off J Am Soc Clin Oncol. 2007;25:493–500.
Valentim L, Laurence KM, Townsend PA, et al. Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury. J Mol Cell Cardiol. 2006;40:846–52.
Article CAS PubMed Google Scholar
Vejpongsa P, Yeh ET. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther. 2014;95:45–52.
Article CAS PubMed Google Scholar
Vrooman LM, Neuberg DS, Stevenson KE, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer (Oxford, England: 1990). 2011;47:1373–9.
Wang Y, Lu X, Wang X, et al. atg7-based autophagy activation reverses doxorubicin-induced cardiotoxicity. Circ Res. 2021;129:e166–82.
Article CAS PubMed PubMed Central Google Scholar
Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptations. Nat Cell Biol. 2007;9:1102–9.
Article CAS PubMed Google Scholar
Xu Z, Jin Y, Gao Z, et al. Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib. Autophagy. 2022;18:1152–73.
Article CAS PubMed Google Scholar
Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–42.
Comments (0)